Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Stakes

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jun 05, 2022 11:48pm

105 Views

Post# 34733110

RE:Stakes

TheMadMonk wrote: I think that we should make this interesting, it can only be called a bet if there is something at stake. I would like to propose a winner stays; the loser goes kind of wager. If on September 23rd, 2022 the share price of ATE is at $0.45 or less, Mugsy stops posting in this chat room, however if the share price is at $0.46 or higher, Stutters agrees to never post again on the ATE board under any of his current or any new user names. Thoughts?

It is interesting that since we put baby in the corner with this bet - Stockings has been doing double duty. Full of p and vinegar because he feels cornered.

hmmmmm !

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program